Yves Gonnissen, PhD (on behalf of Regon BVBA)
Managing Director AmatsiSEPS
Chief Executive Officer
Yves Gonnissen founded SEPS Pharma in 2007 and successfully completed a seed capital round in 2008 led by The Investment Company for Limburg. Since the company’s foundation he incorporated a hybrid business model combining internal product development programs and drug product development services. In 2002 he started his professional career at Janssen Pharmaceutica (a subsidiary of Johnson & Johnson). As a pharmaceutical product developer he was involved in formulation and process development via spray drying of Intelence®, a novel NNRTI HIV drug. Yves holds a Master’s degree in Bioscience Engineering (Chemistry) from the University of Leuven in Belgium. He obtained his PhD at Ghent University in Belgium where he pursued his research interests in the fields of pharmaceutical technology and pharmaceutical drug product development. In 2015 SEPS Pharma was acquired by Amatsigroup and changed its name to AmatsiSEPS.
Jody Voorspoels, PhD (on behalf of Galeno BVBA)
Chief Scientific Officer
Jody Voorspoels joined SEPS Pharma as Chief Scientific Officer and Head of the Pharmaceutical Development Division in July 2009 from Janssen Pharmaceutica (a subsidiary of Johnson & Johnson) where he was responsible for the development of solid dosage forms. He has a broad experience in the formulation and process development of anti-infective, CNS, metabolic and oncology drugs and developed immediate and controlled release systems for water soluble to poorly soluble drugs. He obtained two Johnson & Johnson awards for his work on the formulation and spray drying technology for Intelence®, a novel NNRTI HIV drug. He started his professional career at Tibotec (a subsidiary of Johnson & Johnson) in 2000. Jody holds a Master’s degree in Pharmaceutical Sciences from Ghent University in Belgium where he also obtained his PhD focusing on pharmaceutical technology. In 2015 SEPS Pharma was acquired by Amatsigroup and changed its name to AmatsiSEPS.